A Phase 3 interventional study of Placebo and Vemurafenib in Malignant Melanoma, sponsored by Hoffmann-La Roche. Completed at 156 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-02.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.
Among the 27 studies testing cobimetinib in Melanoma, this one has the largest enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 2nd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
Ages 19+
N.N. Petrov National Medical Research Center of Oncology · Sites in Russian Federation
Ages 18–85 · Healthy volunteers
Cancer Research UK · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cobimetinib is the treatment under test here. Read study by study →
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 4
First in 2011; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 495 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 45 across the 27 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
57 studies in Melanoma by Hoffmann-La Roche: none open now, 4 under way, none of them phase 3. Of 52 finished, 34 (65%) have results posted.
Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 52 interventional ones that give a count, is one of 12 that started in 2013, is one of 6 in phase 3, and was the 21st registered.
Hoffmann-La Roche’s Melanoma studies by the year they started, since 2004.
1 of the studies testing cobimetinib in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04835805Genentech, Inc.A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing cobimetinib in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 57 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with active central nervous system (CNS) lesions (including carcinomatous meningitis) are excluded. However, participants are eligible if:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
Drug: Placebo · Drug: Vemurafenib
Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
Drug: Vemurafenib · Drug: Cobimetinib
Placebo supplied as tablets
Vemurafenib supplied as tablets
Also known as: RO518426
Cobimetinib supplied as tablets
Also known as: GDC-0973, RO5514041, XL518
Progression-free Survival
Progression-free survival was defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator using Response Evaluation Criteria in Solid Tumors v1.1, or death from any cause, whichever came first. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.
Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Overall Survival
Overall survival was defined as the time from randomization until the date of death from any cause.
Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Percentage of Participants With an Objective Response
An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart. Responses were determined by Response Evaluation Criteria in Solid Tumors v1.1. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter of target lesions.
Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Duration of Response
Duration of response was defined as the time from first occurrence of a documented confirmed objective response until the time of disease progression, as determined by investigator review of tumor assessments using Response Evaluation Criteria in Solid Tumors v1.1 or death from any cause during the study. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.
Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
| Milestone | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| Started | 247 | 248 |
| Completed | 0 | 0 |
| Not completed | 247 | 248 |
| Withdrew: Death | 157 | 167 |
| Withdrew: Lost to follow-up | 4 | 8 |
| Withdrew: Other | 2 | 4 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Study terminated by spon6sor | 59 | 48 |
| Withdrew: Withdrawal by subject | 21 | 20 |
| Milestone | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| Started | 248 | 245 |
| Completed | 0 | 0 |
| Not completed | 248 | 245 |
| Withdrew: Death | 158 | 165 |
| Withdrew: Lost to follow-up | 4 | 8 |
| Withdrew: Other | 2 | 4 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Study terminated by sponsor | 60 | 47 |
| Withdrew: Withdrawal by subject | 20 | 20 |
Progression-free survival was defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator using Response Evaluation Criteria in Solid Tumors v1.1, or death from any cause, whichever came first. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.
| Months | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| Primary Analysis: 9 May 2014 | 9.90 (9.00 to NA) | 6.20 (5.55 to 7.39) |
| Post hoc Efficacy Analysis: 16 January 2015 | 12.30 (9.50 to 13.40) | 7.20 (5.60 to 7.50) |
| Extended 5-Year Analysis: 21 July 2019 | 12.60 (9.50 to 14.80) | 7.20 (5.60 to 7.50) |
Overall survival was defined as the time from randomization until the date of death from any cause.
| Months | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| Primary Analysis 9 May 2014 | NA (NA to NA) | NA (NA to NA) |
| Post hoc Analysis 16 January 2015 | NA (20.70 to NA) | 17.00 (15.00 to NA) |
| Final Analysis 28 August 2015 | 22.30 (20.3 to NA) | 17.40 (15.00 to 19.8) |
| Extended 5-year Analysis 21 July 2019 | 22.50 (20.30 to 28.80) | 17.40 (15.00 to 19.80) |
An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart. Responses were determined by Response Evaluation Criteria in Solid Tumors v1.1. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter of target lesions.
| Percentage of participants | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| Primary Analysis: 9 May 2014 | 67.60 (61.39 to 73.41) | 44.80 (38.46 to 51.18) |
| Post hoc Efficacy Analysis: 16 January 2015 | 69.60 (63.50 to 75.30) | 50.00 (43.60 to 56.40) |
| Extended 5-Year Analysis: 21 July 2019 | 69.60 (63.49 to 75.31) | 49.60 (43.21 to 55.99) |
Duration of response was defined as the time from first occurrence of a documented confirmed objective response until the time of disease progression, as determined by investigator review of tumor assessments using Response Evaluation Criteria in Solid Tumors v1.1 or death from any cause during the study. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.
| Months | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| Primary Analysis: 9 May 2014 | NA (9.30 to NA) | 7.29 (5.78 to NA) |
| Extended 5-Year Analysis: 21 July 2019 | 14.65 (12.90 to 19.30) | 9.23 (7.50 to 12.90) |
Collected over Adverse events were collected from the time of each participant's randomization into the study until their last visit until 28 days after the last dose of study drug and during extended 5-year efficacy and safety follow-up analyses (Safety data cut-off: July 2019; up to 7 years, 6 months).. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cobimetinib + Vemurafenib | 160/247 (64.8%) | 105/248 (42.3%) | 239/248 (96.4%) |
| Placebo + Vemurafenib | 164/248 (66.1%) | 71/245 (29%) | 236/245 (96.3%) |
| Event | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| PYREXIAGeneral disorders | 7/248 | 3/245 |
| PNEUMONIAInfections and infestations | 6/248 | 3/245 |
| DEHYDRATIONMetabolism and nutrition disorders | 6/248 | 0/245 |
| PERICARDIAL EFFUSIONCardiac disorders | 0/248 | 4/245 |
| KERATOACANTHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/248 | 4/245 |
| ATRIAL FIBRILLATIONCardiac disorders | 4/248 | 1/245 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 4/248 | 2/245 |
| RASHSkin and subcutaneous tissue disorders | 4/248 | 2/245 |
| ERYSIPELASInfections and infestations | 1/248 | 3/245 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 0/248 | 3/245 |
| Event | Cobimetinib + Vemurafenib | Placebo + Vemurafenib |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 151/248 | 84/245 |
| NAUSEAGastrointestinal disorders | 108/248 | 67/245 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 96/248 | 105/245 |
| RASHSkin and subcutaneous tissue disorders | 101/248 | 97/245 |
| FATIGUEGeneral disorders | 93/248 | 83/245 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 90/248 | 10/245 |
| PHOTOSENSITIVITY REACTIONSkin and subcutaneous tissue disorders | 86/248 | 48/245 |
| PYREXIAGeneral disorders | 77/248 | 60/245 |
| ALOPECIASkin and subcutaneous tissue disorders | 42/248 | 75/245 |
| HYPERKERATOSISSkin and subcutaneous tissue disorders | 31/248 | 74/245 |
Intent-to-treat population: All randomized participants, regardless of whether or not study treatment was received.
| Age, Categorical(Participants) | Cobimetinib + Vemurafenib | Placebo + Vemurafenib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 183 | 179 | 362 |
| >=65 years | 64 | 69 | 133 |
| Age, Continuous(Years) | Cobimetinib + Vemurafenib | Placebo + Vemurafenib | Total |
|---|---|---|---|
| Mean | 54.9 ± 14.0 | 55.3 ± 13.8 | 55.1 ± 13.9 |
| Sex: Female, Male(Participants) | Cobimetinib + Vemurafenib | Placebo + Vemurafenib | Total |
|---|---|---|---|
| Female | 101 | 108 | 209 |
| Male | 146 | 140 | 286 |
| Race/Ethnicity, Customized(Count of Participants) | Cobimetinib + Vemurafenib | Placebo + Vemurafenib | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| More than one race | 1 | 1 | 2 |
| Native Hawaiian or other Pacific Islande | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 |
| White | 227 | 235 | 462 |
| Unknown or Not Reported | 16 | 9 | 25 |
| Other | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Count of Participants) | Cobimetinib + Vemurafenib | Placebo + Vemurafenib | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 12 | 26 |
| Not Hispanic or Latino | 213 | 223 | 436 |
| Not Stated | 16 | 10 | 26 |
| Unknown | 4 | 3 | 7 |
Showing the first 100 of 156 sites across 19 countries. Choose a country and city above to see the rest.
Ran from Jan 2013 to primary completion in May 2014, 16 months.
Results were first posted in Oct 2015, 1 year 5 months after primary completion.
Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 16 months is below that.
Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobimetinib